Pfizer and the rest of the biopharmaceutical industry have faced significant uncertainty. This uncertainty is due to the Trump administration's threats of tariffs on pharmaceutical imports and plans to implement most-favored-nation (MFN) drug pricing, whereby patients in the U.S. would pay the same prices that are paid in other developed countries.

President Donald Trump, who has long argued that the U.S. pays more than it should for prescription medicines, on Tuesday said Pfizer had agreed to cut prices for drugs it sells to the Medicaid progra...

“President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” White House spokesman Kush Desai added to the Daily Beast.